Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: A randomized multicenter study
2007 (English)In: Leukemia, ISSN 0887-6924, Vol. 21, no 4, 627-632 p.Article in journal (Refereed) Published
This randomized study assessed if intravenous iron improves hemoglobin (Hb) response and permits decreased epoetin dose in anemic (Hb 9-11,11 g/dl), transfusion-independent patients with stainable iron in the bone marrow and lymphoproliferative malignancies not receiving chemotherapy. Patients (n=67) were randomized to subcutaneous epoetin beta 30 000 IU once weekly for 16 weeks with or without concomitant intravenous iron supplementation. There was a significantly (P25%) lower in the iron group, as was the total epoetin dose (P=0.051). In conclusion, the Hb increase and response rate were significantly greater with the addition of intravenous iron to epoetin treatment in iron-replete patients and a lower dose of epoetin was required.
Place, publisher, year, edition, pages
2007. Vol. 21, no 4, 627-632 p.
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:liu:diva-40746DOI: 10.1038/sj.leu.2404562Local ID: 54027OAI: oai:DiVA.org:liu-40746DiVA: diva2:261595